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every cancer requires a model for experimental investigations of its etiology and progression. For the past 50 years, the field has relied on 
models of human cells in culture for the biological 
analyses of cancer. Melanoma investigators have 
an abundance of cell lines at their disposal, with 
an estimated 5,000 independent strains estab-
lished by many laboratories. Approximately 200 
human melanoma cell lines have been thoroughly 
characterized for genetic aberrations, global gene 
expression patterns, and biological properties 
such as independence from serum as nutrient, 
anchorage-independent growth in soft agar, inva-
sion in vitro, and tumor and metastasis formation 
in immunodeficient mice. Cells from the different 
stages of melanoma progression have helped us 
understand the stepwise progression from primary 
melanomas to metastases.
Cell lines of human melanoma metastases 
are optimal. These cells can metastasize to most 
organs of an immunodeficient animal—if not 
spontaneously, then after a short period of adap-
tation. Metastatic melanoma cells produce most 
known angiogenic growth factors; they secrete 
most known proteolytic enzymes, hijack fibro-
blasts, control the vasculature, are stimulated 
by otherwise growth inhibitory factors, and can 
mimic the functions of endothelial cells, fibro-
blasts, and even monocytes. The malignant cells 
can also either successfully block the entry of 
drugs or use their excellent transporter systems 
to pump them out. Thus, melanoma cells from 
patients’ metastases have been more widely used 
than cells from any other human tumor. The pros-
tate cancer field, for example, relies primarily on 
three cell lines and their derivatives. There are 
about 150 human breast cancer cell lines in exis-
tence, but the number of “workhorses” in this field 
is barely higher than that for prostate cancer.
The ability of melanoma cells to adapt to chal-
lenging growth conditions has made them the pre-
ferred model of investigators—but with a catch. As 
we all painfully learned in the early 1990s when 
the first melanoma suppressor gene, p16INK4a, was 
described by Kamb and collaborators (1994), 
a melanoma cell in a dish is not the same as a 
cell in a patient. The high frequency of deletions 
of p16INK4a was a culture artifact. Nonetheless, 
this cell cycle inhibitor is silenced in the major-
ity of patients’ melanomas. Cell lines from human 
melanomas continue to be widely used in cancer 
research. The best models mimic the tissue envi-
ronment in patients’ lesions, such as growth in 
three-dimensional matrix substrates or mainte-
nance in immunodeficient mice without any prior 
culture. Each melanoma cell can act as a stem cell 
because it self-renews and induces tumors. The 
data of Morrison and co-workers suggest that one 
in four melanoma cells has stem cell characteris-
tics (Quintana et al., 2008). The most recent data 
from our laboratory suggest that each melanoma 
cell from metastases is tumorigenic in the immu-
nodeficient host.
The second most widely used model is the B16 
murine melanoma cell line, which comes in two 
varieties: F1 has low and F10 has high metastatic 
activities. The B16 cell line was derived more than 
60 years ago from a chemically induced tumor 
in C57BL/6 mice. The F10 variant was derived by 
Fidler in the mid-1970s through serial passages in 
mice (Fidler and Nicolson, 1976). This cell line 
continues to be widely used by many laboratories. 
Its major appeal is its rapid growth in vivo, lead-
ing to tumor-induced death within 2 to 4 weeks; 
the F10 variant is aggressively metastatic to the 
lungs. Because of its strong pigmentation, many 
researchers feel comfortable with this line as a 
model for melanoma. The major problem is that 
most of its adhesion and growth factor profiles are 
unlike those of its human melanoma counterparts. 
Even the enzymes used for invasion into tissues, 
the ability of cells to overpower the immune sys-
tem, the antiapoptotic mechanisms, and many 
other cancer cell hallmarks do not reflect the 
human disease.
What are the B16 melanoma cells good for? 
Not much—because we now have murine mela-
noma models that better reflect the human dis-
ease. B16 melanoma cells should not be used 
for biological studies because the interpretation 
of data derived from this model may lead to false 
conclusions. Instead, investigators should use cells 
from genetic models of melanoma, particularly 
What Is a Good Model for Melanoma?
Journal of Investigative Dermatology (2010) 130, 911–912. 
doi:10.1038/jid.2009.441
editorial
912 Journal of Investigative Dermatology (2010), Volume 130 © 2010 The Society for Investigative Dermatology
the highly metastatic BrafV600E/Pten–/– melanoma model recently 
presented by the McMahon/Bosenberg laboratories (Dankort 
et al., 2009). A similar model was described by the Marais/
Larue laboratories (Dhomen et al., 2009). These murine mela-
nomas have been provided to other laboratories, and cell lines 
are—or will be—available from all models. Even immunolo-
gists will soon be able to work with at least one of the models, 
because the animals are currently crossbred to homozygosity 
in C57BL/6 mice (M. McMahon, M. Bosenberg, and D. Herlyn, 
personal communication).
Which is the best model? There is not one single model but 
several, from both humans and mice. Researchers should be 
encouraged to use human and mouse melanoma cells in par-
allel, preferably those that have been least exposed to stress 
caused by tissue culture.
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